Efficacy analysis of a novel thermochemotherapy scheme with pirarubicin for intermediate- and high-risk nonmuscle-invasive bladder cancer: a single-institution nonrandomized concurrent controlled trial

References

• Ferlay J, Soerjomataram I, Ervik M, et al. GLOBOCAN 2012 v1.0: Estimated cancer incidence, mortality and prevalence worldwide in 2012, 2013, 2015. http://globocan.iarc.fr/Default.aspx.
   Google Scholar
• Compérat E, Larré S, Roupret M, et al. Clinicopathological characteristics of urothelial bladder cancer in patients less than 40 years old. Virchows Arch. 2015;466:589–594.
   PubMed Web of Science ®Google Scholar
• Cambier S, Sylvester RJ, Collette L, et al. EORTC nomograms and risk groups for predicting recurrence, progression, and disease-specific and overall survival in non–muscle-invasive stage Ta–T1 urothelial bladder cancer patients treated with 1–3 years of maintenance bacillus Calmette-Guérin. Eur Urol. 2016;69:60–69.
   PubMed Web of Science ®Google Scholar
• Sylvester RJ, van der Meijden APM, Oosterlinck W, et al. Predicting recurrence and progression in individual patients with stage Ta T1 bladder cancer using EORTC risk tables: a combined analysis of 2596 patients from seven EORTC trials. Eur Urol. 2006;49:466–477.
   PubMed Web of Science ®Google Scholar
• Tan WS, Rodney S, Lamb B, et al. Management of non-muscle invasive bladder cancer: a comprehensive analysis of guidelines from the United States. Europe and Asia. Cancer Treatment Rev. 2016;47:22–31.
   PubMed Web of Science ®Google Scholar
• Bandari J, Maganty A, MacLeod LC, et al. Manufacturing and the market: rationalizing the shortage of bacillus Calmette-Guérin. Eur Urol Focus. 2018;4:481–484.
   PubMedGoogle Scholar
• Chang L, Xiao W, Yang Y, et al. Pseudomonas aeruginosa-mannose–sensitive hemagglutinin inhibits epidermal growth factor receptor signaling pathway activation and induces apoptosis in bladder cancer cells in vitro and in vivo. Urol Oncol Semin Original Invest. 2014;32:36. e11–36. e18.
   Web of Science ®Google Scholar
• Umezawa H, Takahashi Y, Takeuchi T, et al. The absolute structures of THP-adriamycins. J Antibiot. 1984;37:1094–1097.
   PubMed Web of Science ®Google Scholar
• Tsuruo T, Iida H, Tsukagoshi S, et al. 4'-O-tetrahydropyranyladriamycin as a potential new antitumor agent. Cancer Res. 1982;42:1462–1467.
   PubMed Web of Science ®Google Scholar
• Zheng S, Xiong S, Lin F, et al. Pirarubicin inhibits multidrug-resistant osteosarcoma cell proliferation through induction of G2/M phase cell cycle arrest. Acta Pharmacol Sin. 2012;33:832–838.
   PubMed Web of Science ®Google Scholar
• Okamura K, Ono Y, Kinukawa T, et al. Randomized study of single early instillation of (2r)-4-o-tetrahydropyranyl-doxorubicin for a single superficial bladder carcinoma. Cancer. 2002;94:2363–2368.
   PubMed Web of Science ®Google Scholar
• Tanimoto R, Saika T, Ebara S, et al. Prospective randomized controlled trial of postoperative early intravesical chemotherapy with pirarubicin (THP) for solitary non-muscle invasive bladder cancer comparing single and two-time instillation. World J Urol. 2018;36:889–895.
   PubMed Web of Science ®Google Scholar
• Miki T, Nonomura N, Kojima Y, et al. A randomized study on intravesical pirarubicin (THP) chemoprophylaxis of recurrence after transurethral resection of superficial bladder cancer. Hinyokika Kiyo Acta Urologica Japonica. 1997;43:907.
   PubMedGoogle Scholar
• Frey B, Weiss E-M, Rubner Y, et al. Old and new facts about hyperthermia-induced modulations of the immune system. Int J Hyperthermia. 2012;28:528–542.
   PubMed Web of Science ®Google Scholar
• Toraya-Brown S, Fiering S. Local tumour hyperthermia as immunotherapy for metastatic cancer. Int J Hyperthermia. 2014;30:531–539.
   PubMed Web of Science ®Google Scholar
• Matzkin H, Rangel MC, Soloway MS. In vitro study of the effect of hyperthermia on normal bladder cell line and on five different transitional cell carcinoma cell lines. J Urol. 1992;147:1671–1674.
   PubMed Web of Science ®Google Scholar
• van der HA, Verhaegh G, Jansen CFJ, et al. Effect of hyperthermia on the cytotoxicity of 4 chemotherapeutic agents currently used for the treatment of transitional cell carcinoma of the bladder: an in vitro study. J Urol. 2005;173:1375–1380.
   PubMed Web of Science ®Google Scholar
• Cavaliere R, Ciocatto EC, Giovanella BC, et al. Selective heat sensitivity of cancer cells. Biochemical and clinical studies. Cancer. 1967;20:1351–1381.
   PubMed Web of Science ®Google Scholar
• Streffer C. Review: metabolic changes during and after hyperthermia. Int J Hyperthermia. 1985;1:305–319.
   PubMedGoogle Scholar
• Oleson JR. Eugene Robertson Special Lecture Hyperthermia from the clinic to the laboratory: a hypothesis. Int J Hyperthermia. 1995;11:315–322.
   PubMed Web of Science ®Google Scholar
• Datta NR, Ordóñez SG, Gaipl US, et al. Local hyperthermia combined with radiotherapy and-/or chemotherapy: recent advances and promises for the future. Cancer Treat Rev. 2015;41:742–753.
   PubMed Web of Science ®Google Scholar
• Babjuk M, Böhle A, Burger M, et al. EAU guidelines on non–muscle-invasive urothelial carcinoma of the bladder: update 2016. Eur Urol. 2017;71:447–461.
   PubMed Web of Science ®Google Scholar
• Sobin LH, Gospodarowicz MK, Wittekind C, editors. TNM classification of malignant tumours. 7th ed. Hoboken: Wiley-Blackwell; 2009.
   Google Scholar
• Ba M, Cui S, Wang B, et al. Bladder intracavitary hyperthermic perfusion chemotherapy for the prevention of recurrence of non-muscle invasive bladder cancer after transurethral resection. Oncol Rep. 2017;37:2761–2770.
   PubMed Web of Science ®Google Scholar
• Ito A, Shintaku I, Satoh M, et al. Prospective randomized phase II trial of a single early intravesical instillation of pirarubicin (THP) in the prevention of bladder recurrence after nephroureterectomy for upper urinary tract urothelial carcinoma: the THP monotherapy study group trial. J Clin Oncol. 2013;31:1422–1427.
   PubMed Web of Science ®Google Scholar
• Tan WS, Kelly JD. Intravesical device-assisted therapies for non-muscle-invasive bladder cancer. Nat Rev Urol. 2018;15:667–685.
   PubMed Web of Science ®Google Scholar
• Kunimoto S, Miura K, Takahashi Y, et al. Rapid uptake by cultured tumor cells and intracellular behavior of 4'-O-tetrahydropyranyladriamycin. J Antibiot. 1983;36:312–317.
   PubMed Web of Science ®Google Scholar
• Kang M, Jeong CW, Kwak C, et al. Single, immediate postoperative instillation of chemotherapy in non-muscle invasive bladder cancer: a systematic review and network meta-analysis of randomized clinical trials using different drugs. Oncotarget. 2016;7:45479–45488.
   PubMedGoogle Scholar
• Matsumura Y. Cooperative study of therapy of superficial bladder cancer by intravesical instillation of pirarubicin. Am J Clin Oncol. 1990;13:S5–S10.
   PubMed Web of Science ®Google Scholar
• Yamamoto Y, Nasu Y, Saika T, et al. The absorption of pirarubicin instilled intravesically immediately after transurethral resection of superficial bladder cancer. BJU Int. 2001;86:802–804.
   Web of Science ®Google Scholar
• Maruyama T, Higuchi Y, Suzuki T, et al. Double short-time exposure to pirarubicin produces higher cytotoxicity against T24 bladder cancer cells. J Infect Chemother. 2011;17:11–16.
   PubMed Web of Science ®Google Scholar
• Arends TJH, Nativ O, Maffezzini M, et al. Results of a randomised controlled trial comparing intravesical chemohyperthermia with mitomycin C versus bacillus Calmette-Guérin for adjuvant treatment of patients with intermediate- and high-risk non–muscle-invasive bladder cancer. Eur Urol. 2016;69:1046–1052.
   PubMed Web of Science ®Google Scholar
• Colombo R, Da Pozzo LF, Salonia A, et al. Multicentric study comparing intravesical chemotherapy alone and with local microwave hyperthermia for prophylaxis of recurrence of superficial transitional cell carcinoma. J Clin Oncol. 2003;21:4270–4276.
   PubMed Web of Science ®Google Scholar
• Colombo R, Salonia A, Leib Z, et al. Long-term outcomes of a randomized controlled trial comparing thermochemotherapy with mitomycin-C alone as adjuvant treatment for non-muscle-invasive bladder cancer (NMIBC). BJU Int. 2011;107:912–918.
   PubMed Web of Science ®Google Scholar
• Tan WS, Panchal A, Buckley L, et al. Radiofrequency-induced thermo-chemotherapy effect versus a second course of bacillus Calmette-Guérin or institutional standard in patients with recurrence of non–muscle-invasive bladder cancer following induction or maintenance Bacillus Calmette-Guérin Therapy (HYMN): a phase III, open-label, randomised controlled trial. Eur Urol. 2019;75:63–71.
   PubMed Web of Science ®Google Scholar
• Sousa A, Piñeiro I, Rodríguez S, et al. Recirculant hyperthermic Intravesical chemotherapy (HIVEC) in intermediate–high-risk non-muscle-invasive bladder cancer. Int J Hyperthermia. 2016;32:374–380.
   PubMed Web of Science ®Google Scholar
• Sousa A, Inman BA, Piñeiro I, et al. A clinical trial of neoadjuvant hyperthermic intravesical chemotherapy (HIVEC) for treating intermediate and high-risk non-muscle invasive bladder cancer. Int J Hyperthermia. 2014;30:166–170.
   PubMed Web of Science ®Google Scholar
• Ekin RG, Akarken I, Cakmak O, et al. Results of intravesical chemo-hyperthermia in high-risk non-muscle invasive bladder cancer. Asian Pacif J Cancer Prev. 2015;16:3241–3245.
   PubMedGoogle Scholar
• Soria F, Milla P, Fiorito C, et al. Efficacy and safety of a new device for intravesical thermochemotherapy in non-grade 3 BCG recurrent NMIBC: a phase I–II study. World J Urol. 2016;34:189–195.
   PubMed Web of Science ®Google Scholar
• Ekin RG, Akarken I, Zorlu F, et al. Intravesical bacillus Calmette-Guérin versus chemohyperthermia for high-risk non-muscle-invasive bladder cancer. Can Urol Assoc J. 2015;9:278.
   PubMed Web of Science ®Google Scholar
• Tan WS, Palou J, Kelly J, et al. Safety and tolerability analysis of hyperthermic intravesical mitomycin to mitomycin alone in HIVEC I AND HIVEC II: an analysis of 307 patients [abstract MP15-18]. J Urol. 2017;197:e177.
   Web of Science ®Google Scholar